| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-610 | |
| Phytochemical name or plant extracts | Moringa stenopetala extract | |
| PMID | 34610271 | |
| Literature evidence | The findings suggest that Fr-4 and Fr-6 are promising sources of compounds possessing cytotoxic and genotoxic properties. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic extract | |
| Source of phytochemicals or plant Extracts | Moringa stenopetala | |
| Geographical availability | Ethiopia, Kenya | |
| Plant parts | Leaves | |
| Other cancers | Breast cancer, Liver cancer, Colon cancer | |
| Target gene or protein | MTAP, CDKN2A | |
| Gene or Protein evidence | Moreover, relative expression of MTAP and CDKN2A in MCF-7 were increased, whereas expression of p21 and p53 in HCT-116, and APC and TERT in HepG2 were decreased, similar to that of doxorubicin. | |
| Target pathways | NA | |
| IC50 | Fr-4 and Fr-6: 58.3 ± 0.93 μg/mL against MCF-7 35.8 ± 2.44 μg/mL against MCF-7 | |
| Potency | The findings suggest that Fr-4 and Fr-6 are promising sources of compounds possessing cytotoxic and genotoxic properties. | |
| Cell line/ mice model | MCF-7, HepG2, HCT-116 | |
| Additional information | Fractionation of the methanolic extract (E-1) on Diaion HP-20 yielded five fractions (Fr-2 to Fr-6), only Fr-4 and Fr-6 were cytotoxic to breast cancer cells (MCF-7, IC50 = 58.3 ± 0.93 and 35.8 ± 2.44 μg/mL, respectively), human hepatocellular carcinoma cells (HepG2, IC50 = 57.8 ± 1.57 and 39.3 ± 1.90 μg/mL, respectively), and Fr-4 was cytotoxic to human colon cancer cells (HCT-116, IC50 = 94.2 ± 4.9 μg/mL). | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:584747-1 | |
| Safety | NA |